SPRAVATO® for Depression & PTSD
SPRAVATO® is an FDA-approved nasal spray indicated for people who’ve taken 2 or more oral antidepressants and still experience symptoms of depression
Treatment Plan
- SPRAVATO® is taken with an oral antidepressant.
- SPRAVATO® is taken twice a week for the first 4 weeks. After the first 4 weeks, you and your healthcare provider will discuss how often you’ll receive SPRAVATO®.
- SPRAVATO® is administered her in our treatment center and is certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
Spravato Q&A
How is SPRAVATO® nasel spray different than ketamine infusion?
SPRAVATO® (esketamine) CIII nasal spray is a derivative of ketamine. SPRAVATO® is an FDA-approved nasal spray for treatment-resistant depression; it is also approved to treat depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions. Ketamine has not been approved by the FDA to treat depression. Both SPRAVATO® and ketamine are Schedule III controlled substances under the US Controlled Substances Act.
Does insurance cover SPRAVATO® (esketamine) treatments?
Most major insurances (Aetna, Cigna, Horizon, United, Medicare, Medicaid) cover SPRAVATO™ treatments. Additionally, various support programs from Janssen Pharmaceuticals help patients cover the costs of medication and of administration/observation.
Is SPRAVATO® addictive?
No, administered at small doses in a medical setting, there is no evidence that Spravato is addictive (study). In contrast, those who abuse this medication recreationally do so at very high doses to induce psycho-active affects.
Can I take SPRAVATO® on my own?
You cannot take SPRAVATO® on your own. You will administer SPRAVATO® nasal spray yourself under the supervision of a healthcare provider, at a certified SPRAVATO® treatment center. You can choose the location that works best for you; ask your healthcare provider to help find a location. SPRAVATO® cannot be purchased at a pharmacy. Because of the risks for sedation or loss of consciousness, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
Who should NOT take SPRAVATO®?
Do NOT take SPRAVATO® if any of the following applies to you:
You are allergic to esketamine, a similar medicine called ketamine used for anesthesia, or any of the other ingredients in SPRAVATO®.
You have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation) or a history of bleeding in the brain.
Be sure to tell your healthcare provider if you have heart, brain or liver problems; if you have psychosis; or if you are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take SPRAVATO® if you are pregnant. You should not breastfeed if you are taking SPRAVATO®.
Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
How will I know if SPRAVATO® is working?
At each visit, your healthcare provider(s) will ask about your symptoms of depression, side effects and whether or not you are experiencing noticeable improvement. In the clinical studies of SPRAVATO®, a standardized scale called the Montgomery-Åsberg Depression Rating Scale was used to track treatment-resistant depression symptoms and response to treatment.
It’s a good idea to ask your healthcare provider(s) at the start of SPRAVATO® treatment how they will be evaluating your response to treatment, and what you can do to help with that. If your referring healthcare provider is not the same provider treating you with SPRAVATO®, you should ask when, and in what way, your new healthcare provider will be letting your referring provider know how your treatments are going and how you are doing.
